CoChat

Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease

Backus, Lisa I., Belperio, Pamela S., Shahoumian, Troy A., Mole, Larry A. · 2018 · Hepatology
Cited by 160

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease. This observational cohort analysis was comprised of 103,346 genotype 1, 2, and 3, hepatitis C virus–monoinfected patients without advanced liver disease, defined by FIB‐4 ≤3.25 and no diagnosis of cirrhosis, hepatic decompensation, or hepatocellular carcinoma or history of liver transplantation, identified from the Veterans Affairs Hepatitis C Clinical Case Registry. Among 40,664 patients treated with interferon‐free DAA regimens, 39,374 (96.8%) achieved SVR and 1,290 (3.2%) patients were No SVR; 62,682 patients constituted the untreated cohort. The mortality rate for SVR patients of 1.18 deaths/100 patient‐years was significantly lower than the rates for both No SVR patients (2.84 deaths/100 patient‐years; P < 0.001) and untreated patients (3.84 deaths/100 patient‐years; P < 0.001). SVR patients with FIB‐4 <1.45 and 1.45‐3.25 had a 46.0% ( P = 0.036) and 63.2% ( P < 0.001) reduction in mortality rates, respectively, compared to No SVR patients and 66.7% ( P < 0.001) and 70.6% ( P < 0.001) reduction in mortality rates, respectively, compared to untreated patients. In multivariate Cox proportional hazard models controlling for baseline demographics, clinical characteristics, and comorbidities, SVR was independently associated with reduced risk of death compared to No SVR (hazard ratio, 0.44; 95% confidence interval, 0.32‐0.59; P < 0.001) and compared to untreated patients (hazard ratio, 0.32; 95% confidence interval, 0.29‐0.36; P < 0.001). Conclusion : Successfully treating hepatitis C virus with DAAs in patients without clinically apparent advanced liver disease translates into a significant mortality benefit. (H epatology 2018).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.29811

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Backus, L. I., Belperio, P. S., Shahoumian, T. A., & Mole, L. A.
Venue
Hepatology
Published
2018-05-14
Volume
68
Issue
3
Pages
827-838
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2794262809
Cited by
160
References
3
FWCI
15.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.